Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 1997

View Archived Issues

Relaxin-like factor and relaxin analogues described

Novel rapamycin derivatives reported by Novartis

Alcon describes dihydropyridines for ocular use

Fibrinogen antagonists from Glaxo Wellcome

Sanofi Winthrop reveals calpain inhibitors

Novel vasopressin antagonists from Fujisawa

Novel anti-HIV agent reported by Belgian and Mauritian researchers

Antisense compound for asthma shows promise

Alpha-Beta/MycoTox antifungal collaboration

ARIAD and Genovo form gene therapy joint venture

Seragen begins to restructure, sells manufacturing/clinical operations facility

Immunex clones and describes target for RA

National Patent/PolyMASC extend cancer vaccine collaboration

MAA filed for Agouron anti-HIV drug

Cylexin enters clinical trials in newborns

Transdermal buspirone pivotal trials

Antiadhesion product enters clinical trials

Oncogen Science stock changes hands

Multinational clinical trial results for Zenapax

Centocor seeks expansion of ReoPro indications

Deltibant in SIRS

Positive clinical results for doxazosin as BPH Rx

Comparative trial of dorzolamide and acetazolamide

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...